ClinConnect ClinConnect Logo
Search / Trial NCT03464344

Cortical Superficial Siderosis and Risk of Recurrent Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy.

Launched by UNIVERSITY HOSPITAL, TOULOUSE · Mar 7, 2018

Trial Information

Current as of June 27, 2025

Recruiting

Keywords

Intracerebral Hemorrhage Cerebral Amyloid Angiopathy Cortical Superficial Siderosis Magnetic Resonance Imaging

ClinConnect Summary

This clinical trial is studying a condition called cerebral amyloid angiopathy (CAA), which is a common cause of bleeding in the brain, particularly in older adults. The researchers want to find out if a specific marker seen on MRI scans, called cortical superficial siderosis (cSS), can help predict the risk of future bleeding episodes in patients who have recently experienced a type of brain bleed known as lobar intracerebral hemorrhage (ICH). They believe that having cSS might mean a higher chance of experiencing more bleeding in the future.

To participate in this study, individuals must be at least 55 years old and have had a lobar ICH within the last 30 days. They will need to provide consent and have specific MRI images available for review. The trial is open to everyone who meets these requirements, and participants will be monitored to see how their condition progresses. This study is important because it could help doctors better understand the risks associated with CAA and improve care for patients with this condition.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Lobar ICH within 30 days after onset
  • Available brain MRI sequences of adequate quality including fluid-attenuated inversion recovery (FLAIR) and T2\*-weighted gradient-recalled echo (T2\*-GRE) sequences.
  • Modified Boston criteria for probable or possible CAA
  • Age ≥ 55 years
  • Written consent
  • Exclusion Criteria:
  • Secondary brain hemorrhage : vascular malformation (arteriovenous malformation, aneurysm, cavernous); cerebral veinous thrombosis; brain tumor; coagulopathy; vasculitis; hemorrhagic infarction,
  • Infratentorial siderosis
  • Contraindications to MRI
  • Neurosurgical intervention before inclusion,
  • Progressive neoplasm
  • Patient without affiliation to the french social security
  • Patient under guardianship

About University Hospital, Toulouse

The University Hospital of Toulouse is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care, the hospital integrates cutting-edge scientific inquiry with comprehensive clinical services. Its multidisciplinary team of healthcare professionals collaborates with renowned researchers to facilitate pioneering studies across various medical fields, aiming to enhance treatment options and improve patient outcomes. As a prominent institution in the region, the University Hospital of Toulouse is committed to fostering an environment of excellence in both education and research within the healthcare community.

Locations

Paris, , France

Bordeaux, , France

Montpellier, , France

Toulouse Cedex 9, , France

Patients applied

0 patients applied

Trial Officials

Nicolas RAPOSO, MD

Principal Investigator

University Hospital, Toulouse

Lionel CALVIERE

Principal Investigator

University Hospital, Toulouse

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials